Desnick RJ, Dean KJ, Grabowski GA, Bishop DF, Sweeley CC. Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease. Birth Defects Orig Artic Ser. 1980;16(1):393–413.
CAS
PubMed
Google Scholar
El-Abassi R, Singhal D, England JD. Fabry’s disease. J Neurol Sci. 2014;344(1–2):5–19.
Article
CAS
PubMed
Google Scholar
Ellaway C. Paediatric Fabry disease. Transl Pediatr. 2016;5(1):37–42.
PubMed
PubMed Central
Google Scholar
Kint JA. The enzyme defect in Fabry’s disease. Nature. 1970;227(5263):1173.
Article
CAS
PubMed
Google Scholar
Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res. 2008;64(5):550–5.
Article
PubMed
Google Scholar
Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol Genet Genomic Med. 2018;6:492.
Article
CAS
PubMed Central
Google Scholar
Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry registry. Mol Genet Metab. 2016;119(1–2):151–9.
Article
CAS
PubMed
Google Scholar
Choi JH, Lee BH, Heo SH, Kim GH, Kim YM, Kim DS, et al. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype. Medicine (Baltimore). 2017;96(29):e7387.
Article
Google Scholar
Veloso VSP, Ataides TL, Canziani MEF, Veloso MP, da Silva NA, Barreto DV, et al. A novel missense GLA mutation (p.G35V) detected in hemodialysis screening leads to severe systemic manifestations of Fabry disease in men and women. Nephron. 2018;138(2):147–56.
Article
CAS
PubMed
Google Scholar
Davies JP, Winchester BG, Malcolm S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet. 1993;2(7):1051–3.
Article
CAS
PubMed
Google Scholar
du Moulin M, Koehn AF, Golsari A, Dulz S, Atiskova Y, Patten M, et al. The mutation p.D313Y is associated with organ manifestation in Fabry disease. Clin Genet. 2017;92(5):528–33.
Article
PubMed
CAS
Google Scholar
Lee HJ, Hsu TR, Hung SC, Yu WC, Chu TH, Yang CF, et al. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>a mutation. BMC Neurol. 2017;17(1):25.
Article
PubMed
PubMed Central
Google Scholar
Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539–48.
Article
PubMed
Google Scholar
Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000;84(2–3):361–5.
Article
CAS
PubMed
Google Scholar
Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003;162(11):767–72.
Article
PubMed
Google Scholar
Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76(3):246–51.
CAS
PubMed
Google Scholar
Fervenza FC, Torra R, Lager DJ. Fabry disease: an underrecognized cause of proteinuria. Kidney Int. 2008;73(10):1193–9.
Article
CAS
PubMed
Google Scholar
Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int. 1978;13(3):223–35.
Article
CAS
PubMed
Google Scholar
Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102–11.
Article
PubMed
PubMed Central
Google Scholar
Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28(10):1228–35.
Article
PubMed
Google Scholar
Senechal M, Germain DP. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet. 2003;63(1):46–52.
Article
CAS
PubMed
Google Scholar
Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005;96(6):842–6.
Article
PubMed
Google Scholar
Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry’s disease. Lancet Neurol. 2006;5(9):791–5.
Article
PubMed
Google Scholar
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med. 2009;11(11):790–6.
Article
PubMed
Google Scholar
Beck M. Demographics of FOS - the Fabry outcome survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford; 2006.
Google Scholar
Ramaswami U, Parini R, Pintos-Morell G. Natural history and effects of enzyme replacement therapy in children and adolescents with Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 31.
Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743–9.
Article
CAS
PubMed
Google Scholar
Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol. 2008;53(4):416–23.
Article
PubMed
Google Scholar
van der Tol L, Sminia ML, Hollak CE, Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016;100(1):3–8.
Article
PubMed
Google Scholar
Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: data from the Fabry outcome survey. Br J Ophthalmol. 2007;91(2):210–4.
Article
PubMed
Google Scholar
Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS One. 2015;10(3):e0120814.
Article
PubMed
PubMed Central
CAS
Google Scholar
San Roman I, Rodriguez ME, Caporossi O, Zoppetti C, Sodi A, Mecocci A, et al. Computer assisted retinal vessel tortuosity evaluation in novel mutation Fabry disease: towards new prognostic markers. Retina. 2017;37(3):592–603.
Article
PubMed
Google Scholar
Sodi A, Guarducci M, Vauthier L, Ioannidis AS, Pitz S, Abbruzzese G, et al. Computer assisted evaluation of retinal vessels tortuosity in Fabry disease. Acta Ophthalmol. 2013;91(2):e113–9.
Article
PubMed
Google Scholar
Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Exp Ophthalmol. 2005;33(2):164–8.
Article
PubMed
Google Scholar
Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2017;22(4):843–49.
Article
PubMed
CAS
Google Scholar
Orlando RG, Dangel ME, Schaal SF. Clinical experience and grading of amiodarone keratopathy. Ophthalmology. 1984;91(10):1184–7.
Article
CAS
PubMed
Google Scholar
Kuroda M, Hirami Y, Hata M, Mandai M, Takahashi M, Kurimoto Y. Intraretinal hyperreflective foci on spectral-domain optical coherence tomographic images of patients with retinitis pigmentosa. Clin Ophthalmol. 2014;8:435–40.
Article
PubMed
PubMed Central
Google Scholar
Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116(5):914–20.
Article
PubMed
Google Scholar
Deak GG, Bolz M, Kriechbaum K, Prager S, Mylonas G, Scholda C, et al. Effect of retinal photocoagulation on intraretinal lipid exudates in diabetic macular edema documented by optical coherence tomography. Ophthalmology. 2010;117(4):773–9.
Article
PubMed
Google Scholar
Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53(9):5814–8.
Article
CAS
PubMed
Google Scholar
Parodi MB, Romano F, Sacconi R, Casati S, Marchini G, Bandello F, et al. Intraretinal hyperreflective foci in best vitelliform macular dystrophy. Retina. 2017.
Okuwobi IP, Fan W, Yu C, Yuan S, Liu Q, Zhang Y, et al. Automated segmentation of hyperreflective foci in spectral domain optical coherence tomography with diabetic retinopathy. J Med Imaging (Bellingham). 2018;5(1):014002.
Google Scholar
Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet. 2003;24(3):129–39.
Article
PubMed
Google Scholar
Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol. 1979;97(4):671–6.
Article
CAS
PubMed
Google Scholar
Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford; 2006.
Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123(2):148–53.
Article
CAS
PubMed
Google Scholar
Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naive Fabry disease patients. BMC Pharmacol Toxicol. 2017;18(1):43.
Article
PubMed
PubMed Central
CAS
Google Scholar
Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121(2):157–61.
Article
CAS
PubMed
Google Scholar
Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1–2):57–61.
Article
CAS
PubMed
Google Scholar
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105(8):2812–7.
Article
CAS
PubMed
PubMed Central
Google Scholar